Transfer RNA supplementation rescues HARS deficiency in a humanized yeast model of Charcot-Marie-Tooth disease
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkae996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Sarah D P Wilhelm und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, The University of Western Ontario, London, Ontario N6A 5C1, Canada. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Saccharomyces cerevisiae, RNA, Transfer, Histidine-tRNA Ligase. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, Canada Research Chairs, CIHR.
Abstract (Originalsprache)
Aminoacyl-tRNA synthetases are indispensable enzymes in all cells, ensuring the correct pairing of amino acids to their cognate tRNAs to maintain translation fidelity. Autosomal dominant mutations V133F and Y330C in histidyl-tRNA synthetase (HARS) cause the genetic disorder Charcot-Marie-Tooth type 2W (CMT2W). Treatments are currently restricted to symptom relief, with no therapeutic available that targets the cause of disease. We previously found that histidine supplementation alleviated phenotypic defects in a humanized yeast model of CMT2W caused by HARS V155G and S356N that also unexpectedly exacerbated the phenotype of the two HARS mutants V133F and Y330C. Here, we show that V133F destabilizes recombinant HARS protein, which is rescued in the presence of tRNAHis. HARS V133F and Y330C cause mistranslation and cause changes to the proteome without activating the integrated stress response as validated by mass spectrometry and growth defects that persist with histidine supplementation. The growth defects and reduced translation fidelity caused by V133F and Y330C mutants were rescued by supplementation with human tRNAHis in a humanized yeast model. Our results demonstrate the feasibility of cognate tRNA as a therapeutic that rescues HARS deficiency and ameliorates toxic mistranslation generated by causative alleles for CMT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, The University of Western Ontario, London, Ontario N6A 5C1, Canada.
- Bioinformatics Solutions Inc, Waterloo, Ontario, N2L 3K8 Canada.
- Department of Chemistry, The University of Western Ontario, London, Ontario N6A 5C1, Canada.
- Children's Health Research Institute, London, ON, N6C 4V3 Canada.
ORCID-Profile: Patrick O'Donoghue, Ilka U Heinemann
Förderung
- Natural Sciences and Engineering Research Council of Canada
- Canada Research Chairs
- CIHR
- Ontario Ministry of Research and Innovation
- Huntington Society of Canada Endowed Research Chair
- Rare Disease Models and Mechanism
- Canada Graduate Scholarship (Masters program)
- Canadian Institutes of Health Research
Zitieren
APA
Wilhelm, S. D. P., Kakadia, J. H., Beharry, A., Kenana, R., Hoffman, K. S., O'Donoghue, P., & Heinemann, I. U. (2024). Transfer RNA supplementation rescues HARS deficiency in a humanized yeast model of Charcot-Marie-Tooth disease. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae996
Vancouver
Wilhelm SDP, Kakadia JH, Beharry A, Kenana R, Hoffman KS, O'Donoghue P, et al. Transfer RNA supplementation rescues HARS deficiency in a humanized yeast model of Charcot-Marie-Tooth disease. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae996
BibTeX
@article{Wilhelm2024,
author = {Wilhelm, Sarah D P and Kakadia, Jenica H and Beharry, Aruun and Kenana, Rosan and Hoffman, Kyle S and O'Donoghue, Patrick and Heinemann, Ilka U},
title = {Transfer RNA supplementation rescues HARS deficiency in a humanized yeast model of Charcot-Marie-Tooth disease},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkae996}
}
EUVIMED